Vaccinex Reports Third Quarter 2022 Results and Provides Corporate Update

14.11.2022 - Continued Progress in Pepinemab Oncology and Neurology Clinical ProgramsPromising initial responses in Phase 1b/2 open-label KEYNOTE B84 study of pepinemab with KEYTRUDA in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma Patient ...

Related Keywords

Cambridge ,Cambridgeshire ,United Kingdom ,John Mullaly ,Neuroinflammation Evans ,Maurice Zauderer ,Pepinemab Trastuzumab ,Lifesci Advisors ,Vaccinex Inc ,Society For Immunotherapy Of Cancer ,Winship Cancer Institute Of Emory University ,Nasdaq ,Exchange Commission ,Development Expenses ,Huntington Study Group ,Activmab Platform Technology ,European Huntington Disease Network ,Association International Conference ,European Society For Medical Oncology ,November Medical Meetings ,Study Group ,Chief Executive Officer ,Disease Cognitive Assessment Battery ,Winship Cancer Institute ,Emory University ,Medical Oncology ,Nature Medicine ,European Huntington ,Disease Network ,Platform Technology ,Neck Cancer ,Adoptivet Cell Therapy Following ,Pulsed Dendritic Cell Vaccine ,Positive Breast Cancer ,Three Months Ended September ,Cash Equivalents ,Comprehensive Loss ,Surface Oncology ,Material Transfer Agreements ,Annual Report ,Sci Advisors ,Consolidated Balance Sheets ,Consolidated Statements ,Months Ended September ,